3-(Cyclopropylmethoxy)-4-(difluoromethoxy)benzoic Acid → 2-{1-[3-(Cyclopropylmethoxy)-4-(difluoromethoxy)benzoyl]piperidin-4-yl}-5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one

Beteiligte Stoffe

Rolle	Name	HCID	Einwaage
Edukt	3-(Cyclopropylmethoxy)-4-(difluoromethoxy)benzoic Acid	HCID 2394006	—
Edukt	5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-piperidin-4-yl-2,4-dihydro-3H-pyrazol-3-one hydrochloride	HCID 66616406	—
Produkt	2-{1-[3-(Cyclopropylmethoxy)-4-(difluoromethoxy)benzoyl]piperidin-4-yl}-5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one	HCID 46204962	—

Reaktionsschritte

The title compound is prepared analogously as described for GP2-WU2 using 5-(3,4-dimethoxyphenyl)-4,4-dimethyl-2-(piperidin-4-yl)-2,4-dihydro-3H-pyrazol-3-one (compound B1) and 3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid as starting compounds. The crude product is purified by chromatography (amino phase silica gel and DCM) to yield the title compound.

Herkunft & Nachweise

DOI	10.6084/m9.figshare.5104873.v1
Patentnummer	US09340522B2
Quelldatensatz	uspto-grants-2016_05
ORD ID	ord-548ba1cfc2464c05b9dbb4f1cc1f3524
Quellennotiz	uspto-grants-2016_05